BioCentury | Nov 30, 2018
Targets & Mechanisms

Adhesion targets emerge at ASH 2018

...have a mature phenotype and typically have been exposed to cytomegalovirus (CMV). Fate Therapeutics has Fate-NK100...
BioCentury | Apr 13, 2018
Clinical News

Fate reports Phase I data for Fate-NK100 in ovarian cancer

...from two evaluable patients with ovarian cancer in the Phase I APOLLO trial showing that Fate-NK100...
...ovarian, fallopian tube or primary peritoneal cancer. Patients are receiving a single intraperitoneal infusion of Fate-NK100...
...by a short course of intraperitoneal IL-2. The Masonic Cancer Center is sponsoring the trial. Fate-NK100...
BioCentury | Mar 15, 2018
Product R&D

Engineered to kill

...Umbilical cord blood-derived expanded NK cells Phase I AML; MM CARs Fate Therapeutics Inc. (NASDAQ:FATE) Fate-NK100...
BioCentury | Feb 16, 2018
Product R&D

Banking on the placenta

...differentiated from cord blood progenitors Fate Therapeutics Inc. is delivering an NK cell subset dubbed FATE-NK100...
BioCentury | Dec 8, 2017
Clinical News

Fate reports initial Phase I data for Fate-NK100 in AML

...7 cells/kg Fate-NK100 achieved a morphologic leukemia-free state, and a patient receiving 1x10 7 cells/kg Fate-NK100...
...3 dose cohorts of 1x10 7 , 2x10 7 and up to 1x10 8 cells/kg Fate-NK100...
...measured by bone marrow morphology and flow cytometry, leukemia-free survival (LFS) and overall survival (OS). Fate-NK100...
BioCentury | Sep 11, 2017
Distillery Therapeutics

Cancer

...inhibitor plus Herceptin. Ongoing work by Fate Therapeutics Inc. has included Phase I testing of Fate-NK100...
..."Fate's Killer Memory." BioCentury Innovations (Aug. 31, 2017)). Fate has also submitted an IND for Fate-NK100...
...Aug. 8, 2017 doi:10.1158/0008-5472.CAN-17-0799 CONTACT: Jeffrey S. Miller, University of Minnesota, Minneapolis, Minn. email: mille011@umn.edu Michael Leviten Fate-NK100 Fate...
BioCentury | Aug 31, 2017
Translation in Brief

Fate’s killer memory

...Fate Therapeutics Inc. has published the cell culture methodology behind Fate-NK100 , its adoptive memory NK...
...of the Masonic Cancer Center (MCC) where Fate recently started a Phase I trial of Fate-NK100...
...collaborators at Fate described how they produce the CD57 -positive memory NK cells used in Fate-NK100...
Items per page:
1 - 7 of 7